-
1
-
-
0028179054
-
Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor
-
COI: 1:CAS:528:DyaK2cXltVKht70%3D, PID: 8178155
-
Grabstein, K. H. et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264, 965–968 (1994).
-
(1994)
Science
, vol.264
, pp. 965-968
-
-
Grabstein, K.H.1
-
2
-
-
41149132993
-
Twelve immunotherapy drugs that could cure cancers
-
COI: 1:CAS:528:DC%2BD1cXlsFejtLo%3D, PID: 18364014
-
Cheever, M. A. Twelve immunotherapy drugs that could cure cancers. Immunological Reviews 222, 357–368 (2008).
-
(2008)
Immunological Reviews
, vol.222
, pp. 357-368
-
-
Cheever, M.A.1
-
3
-
-
0035102242
-
Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy
-
COI: 1:CAS:528:DC%2BD3MXivFOqur4%3D, PID: 11239443
-
Waldmann, T. A., Dubois, S. & Tagaya, Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 14, 105–10 (2001).
-
(2001)
Immunity
, vol.14
, pp. 105-110
-
-
Waldmann, T.A.1
Dubois, S.2
Tagaya, Y.3
-
4
-
-
33746547247
-
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
-
COI: 1:CAS:528:DC%2BD28Xnt1yisb0%3D
-
Waldmann, T. A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nature Review Immunology 6, 595–601 (2006).
-
(2006)
Nature Review Immunology
, vol.6
, pp. 595-601
-
-
Waldmann, T.A.1
-
5
-
-
0035399559
-
The Sushi domain of soluble IL-15 receptor alpha is essential for binding IL-15 and inhibiting inflammatory and allogenic responses in vitro and in vivo
-
COI: 1:CAS:528:DC%2BD3MXkslSqu74%3D
-
Wei, X. et al. The Sushi domain of soluble IL-15 receptor alpha is essential for binding IL-15 and inhibiting inflammatory and allogenic responses in vitro and in vivo. Journal of Immunology 167, 277–282 (2001).
-
(2001)
Journal of Immunology
, vol.167
, pp. 277-282
-
-
Wei, X.1
-
6
-
-
84923017215
-
Interleukin-15: new kid on the block for antitumor combination therapy
-
Van den Bergh, J. M., Van Tendeloo, V. F. & Smits, E. L. Interleukin-15: new kid on the block for antitumor combination therapy. Cytokine Growth Factor Review 26, 15–24 (2015).
-
(2015)
Cytokine Growth Factor Review
, vol.26
, pp. 15-24
-
-
Van den Bergh, J.M.1
Van Tendeloo, V.F.2
Smits, E.L.3
-
7
-
-
33750335080
-
Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo
-
COI: 1:CAS:528:DC%2BD28XhtFSns73O
-
Stoklasek, T. A., Schluns, K. S. & Lefrancois, L. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. Journal of Immunology 177, 6072–6080 (2006).
-
(2006)
Journal of Immunology
, vol.177
, pp. 6072-6080
-
-
Stoklasek, T.A.1
Schluns, K.S.2
Lefrancois, L.3
-
8
-
-
0034234925
-
Differences of biodistribution, pharmacokinetics, and tumor targeting between interleukins 2 and 15
-
COI: 1:CAS:528:DC%2BD3cXkvFChsbw%3D, PID: 10910071
-
Kobayashi, H., Carrasquillo, J. A., Paik, C. H., Waldmann, T. A. & Tagaya, Y. Differences of biodistribution, pharmacokinetics, and tumor targeting between interleukins 2 and 15. Cancer Research 60, 3577–3583 (2000).
-
(2000)
Cancer Research
, vol.60
, pp. 3577-3583
-
-
Kobayashi, H.1
Carrasquillo, J.A.2
Paik, C.H.3
Waldmann, T.A.4
Tagaya, Y.5
-
9
-
-
68549104128
-
E. coli expression and purification of human and cynomolgus IL-15
-
COI: 1:CAS:528:DC%2BD1MXhtVSmtrnE, PID: 19435602
-
Ward, A. et al. E. coli expression and purification of human and cynomolgus IL-15. Protein Expression and Purification 68, 42–48 (2009).
-
(2009)
Protein Expression and Purification
, vol.68
, pp. 42-48
-
-
Ward, A.1
-
11
-
-
33644975335
-
Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 × IL-15R alpha fusion proteins
-
COI: 1:CAS:528:DC%2BD28XksFOlsA%3D%3D, PID: 16284400
-
Mortier, E. et al. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 × IL-15R alpha fusion proteins. Journal of Biological Chemistry 281, 1612–9 (2006).
-
(2006)
Journal of Biological Chemistry
, vol.281
, pp. 1612-1619
-
-
Mortier, E.1
-
12
-
-
42149162887
-
Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action
-
COI: 1:CAS:528:DC%2BD1cXhsVShtL4%3D
-
Dubois, S., Patel, H. J., Zhang, M., Waldmann, T. A. & Muller, J. R. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. Journal of Immunology 180, 2099–2106 (2008).
-
(2008)
Journal of Immunology
, vol.180
, pp. 2099-2106
-
-
Dubois, S.1
Patel, H.J.2
Zhang, M.3
Waldmann, T.A.4
Muller, J.R.5
-
13
-
-
37549007225
-
Crystal Structure of the interleukin-15.interleukin-15 receptor alpha complex: insights into trans and cis presentation
-
COI: 1:CAS:528:DC%2BD2sXhsVamurvL, PID: 17947230
-
Olsen, S. K. et al. Crystal Structure of the interleukin-15.interleukin-15 receptor alpha complex: insights into trans and cis presentation. Journal of Biological Chemistry 282, 37191–37204 (2007).
-
(2007)
Journal of Biological Chemistry
, vol.282
, pp. 37191-37204
-
-
Olsen, S.K.1
-
14
-
-
84892371627
-
Protein disulfide engineering
-
Dombkowskia, A., Sultanab, K. Z. & Craig, D. B. Protein disulfide engineering. FEBS Letters. 588, 206–212 (2014).
-
(2014)
FEBS Letters.
, vol.588
, pp. 206-212
-
-
Dombkowskia, A.1
Sultanab, K.Z.2
Craig, D.B.3
-
15
-
-
0024564552
-
Control of enzyme activity by an engineered disulfide bond
-
Matsumara, M. & Mathews, B. W. Control of enzyme activity by an engineered disulfide bond. Science 243, 92–794 (1989).
-
(1989)
Science
, vol.243
, pp. 92-794
-
-
Matsumara, M.1
Mathews, B.W.2
-
16
-
-
0022998684
-
In vivo formation and stability of engineered disulfide bonds in subtilisin
-
COI: 1:CAS:528:DyaL28Xit1Wgtrg%3D, PID: 3516996
-
Wells, J. A. & Powers, D. B. In vivo formation and stability of engineered disulfide bonds in subtilisin. Journal of Biological Chemistry 261, 6564–6570 (1986).
-
(1986)
Journal of Biological Chemistry
, vol.261
, pp. 6564-6570
-
-
Wells, J.A.1
Powers, D.B.2
-
18
-
-
0029766875
-
Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments
-
COI: 1:CAS:528:DyaK28XmtFagsr4%3D, PID: 9631086
-
Reiter, Y., Brinkmann, U., Lee, B. & Pastan, I. Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. Nature Biotechnology 14, 1239–45 (1996).
-
(1996)
Nature Biotechnology
, vol.14
, pp. 1239-1245
-
-
Reiter, Y.1
Brinkmann, U.2
Lee, B.3
Pastan, I.4
-
19
-
-
84555186831
-
A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity
-
COI: 1:CAS:528:DC%2BC38XitFOjsLk%3D, PID: 22101015
-
Liu, W. et al. A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity. Protein Engineering, Design and Selection 25, 1–6 (2012).
-
(2012)
Protein Engineering, Design and Selection
, vol.25
, pp. 1-6
-
-
Liu, W.1
-
20
-
-
34548125264
-
Crystal structure of the IL-15-IL-15Ralpha complex, a cytokine-receptor unit presented in trans
-
COI: 1:CAS:528:DC%2BD2sXptlSkurs%3D, PID: 17643103
-
Chirifu, M. et al. Crystal structure of the IL-15-IL-15Ralpha complex, a cytokine-receptor unit presented in trans. Nature Immunology 8, 1001–1007 (2007).
-
(2007)
Nature Immunology
, vol.8
, pp. 1001-1007
-
-
Chirifu, M.1
-
21
-
-
67649843650
-
Strategies to extend plasma half-lives of recombinant antibodies
-
COI: 1:CAS:528:DC%2BD1MXovFSnsbs%3D, PID: 19489651
-
Kontermann, R. E. Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs 23, 93–109 (2009).
-
(2009)
BioDrugs
, vol.23
, pp. 93-109
-
-
Kontermann, R.E.1
-
23
-
-
81455158710
-
IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization
-
COI: 1:CAS:528:DC%2BC3MXhsFSktL%2FJ, PID: 22019703
-
Han, K. P. et al. IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine 56, 804–10 (2011).
-
(2011)
Cytokine
, vol.56
, pp. 804-810
-
-
Han, K.P.1
-
24
-
-
84892407279
-
The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8+T cells into innate-like effector cells with antitumor activity
-
PID: 24404427
-
Wong, H. C., Jeng, E. K. & Rhode, P. R. The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8+T cells into innate-like effector cells with antitumor activity. Oncoimmunology 2, e26442 (2013).
-
(2013)
Oncoimmunology
, vol.2
-
-
Wong, H.C.1
Jeng, E.K.2
Rhode, P.R.3
-
25
-
-
85065766578
-
-
PCT International Application WO 2015103928 A1 20150716
-
Qu, X. et al. PCT International Application WO 2015103928 A1 20150716 (2015).
-
(2015)
-
-
Qu, X.1
-
26
-
-
85065787562
-
-
PCT International Application WO 2016095642 A1 20160623
-
Qu, X. et al. PCT International Application WO 2016095642 A1 20160623 (2016).
-
(2016)
-
-
Qu, X.1
-
27
-
-
70349482330
-
High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer
-
COI: 1:CAS:528:DC%2BD1MXhtFCis7jK, PID: 19723883
-
Bessard, A., Sole, V., Bouchaud, G., Quemener, A. & Jacques, Y. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer. Molecular Cancer Therapeutics 8, 2736–2745 (2009).
-
(2009)
Molecular Cancer Therapeutics
, vol.8
, pp. 2736-2745
-
-
Bessard, A.1
Sole, V.2
Bouchaud, G.3
Quemener, A.4
Jacques, Y.5
-
28
-
-
84869410452
-
Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15
-
COI: 1:CAS:528:DC%2BC38XhsFOmtLbP, PID: 23104097
-
Ring, A. M. et al. Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nature Immunology 13, 1187–1195 (2012).
-
(2012)
Nature Immunology
, vol.13
, pp. 1187-1195
-
-
Ring, A.M.1
-
29
-
-
0035423368
-
Cutting edge: the mouse NK cell-associated antigen recognized by DX5 monoclonal antibody is CD49b (alpha 2 integrin, very late antigen-2)
-
COI: 1:CAS:528:DC%2BD3MXls1WktLo%3D, PID: 11466327
-
Arase, H., Saito, T., Phillips, J. H. & Lanier, L. L. Cutting edge: the mouse NK cell-associated antigen recognized by DX5 monoclonal antibody is CD49b (alpha 2 integrin, very late antigen-2). J. Immunol. 167, 1141–1144 (2001).
-
(2001)
J. Immunol.
, vol.167
, pp. 1141-1144
-
-
Arase, H.1
Saito, T.2
Phillips, J.H.3
Lanier, L.L.4
-
30
-
-
84960166465
-
Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models
-
COI: 1:CAS:528:DC%2BC28XjvFansg%3D%3D, PID: 26511282
-
Rhode, P. et al. Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models. Cancer Immunology Research 4, 49–60 (2016).
-
(2016)
Cancer Immunology Research
, vol.4
, pp. 49-60
-
-
Rhode, P.1
|